Amgen Halts GDNF Study Following Complete Review of Phase II Trial Data

Citing patient safety concerns and scientific findings, Amgen has confirmed its previous decision to halt clinical trials of the experimental drug GDNF (Glial-cell-lined-derived neurotrophic factor) for Parkinson's disease.

Amgen halted studies of GDNF when scientific results indicated that allowing patients to continue treatment could potentially cause permanent harm, complicating an already devastating disease.

As part of that decision, and based on thorough scientific review, Amgen has also concluded that it will not provide GDNF to the 48 patients who participated in clinical trials that were terminated in the fall of 2004.